KEAP1 and non-small cell lung carcinoma: Recently, an increasing number of biomarkers have been identified to predict the therapeutic efficacy of ICIs in NSCLC, including KEAP1-driven co-mutation events, DDR (DNA damage repair) pathway, APOBEC signature, and others (10–13).